BioCryst Pharmaceuticals (BCRX) Stock Forecast, Price Target & Predictions

OverviewRevenue Ownership Financials Chart Transcripts

BCRX Stock Forecast

BioCryst Pharmaceuticals stock forecast is as follows: an average price target of $16.00 (represents a 109.42% upside from BCRX’s last price of $7.64) and a rating consensus of 'Buy', based on 15 wall street analysts offering a 1-year stock forecast.

BCRX Price Target

The average price target for BioCryst Pharmaceuticals (BCRX) is $16.00 based on 1-year price targets from 15 Wall Street analysts in the past 3 months, with a price target range of $25.00 to $7.00. This represents a potential 109.42% upside from BCRX's last price of $7.64.

BCRX Analyst Ratings

Buy

According to 15 Wall Street analysts, BioCryst Pharmaceuticals's rating consensus is 'Buy'. The analyst rating breakdown for BCRX stock is 0 'Strong Buy' (0.00%), 12 'Buy' (80.00%), 3 'Hold' (20.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

BioCryst Pharmaceuticals Price Target by Analyst

Date	Analyst	Company	Price Target	Price when Published	Price Target/Price when Published	Price Target/Last Closing Price
Aug 06, 2024	Gena Wang	Barclays	$7.00	$7.51	-6.79%	-8.38%
Aug 05, 2024	Maury Raycroft	Jefferies	$11.00	$7.51	46.47%	43.98%
Nov 02, 2022	Liisa Bayko	Evercore ISI	$16.00	$12.38	29.19%	109.42%
Aug 23, 2022	Gena Wang	Barclays	$14.00	$14.32	-2.27%	83.25%
Jan 10, 2022	Ken Cacciatore	Cowen & Co.	$25.00	$14.78	69.15%	227.23%
Nov 03, 2021	Brian Cheng	Cantor Fitzgerald	$21.00	$12.40	69.35%	174.87%
Aug 09, 2021	Maury Raycroft	Jefferies	$19.00	$17.65	7.65%	148.69%

Row per page

Go to

The latest BioCryst Pharmaceuticals stock forecast, released on Aug 06, 2024 by Gena Wang from Barclays, set a price target of $7.00, which represents a -6.79% decrease from the stock price at the time of the forecast ($7.51), and a -8.38% decrease from BCRX last price ($7.64).

BioCryst Pharmaceuticals Price Target by Period

	1M	3M	12M
# Anlaysts	-	-	2
Avg Price Target	-	-	$9.00
Last Closing Price	$7.64	$7.64	$7.64
Upside/Downside	-100.00%	-100.00%	17.80%

In the current month, the average price target of BioCryst Pharmaceuticals stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to BioCryst Pharmaceuticals's last price of $7.64. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades

Date	Company	Previous Rating	New Rating	Rating Change
Nov 04, 2024	Piper Sandler	Overweight	Overweight	Hold
Nov 04, 2024	Bank of America Securities	Buy	Buy	Hold
Aug 06, 2024	JMP Securities	Outperform	Outperform	Hold
Aug 06, 2024	Barclays	Equal-Weight	Equal-Weight	Hold
Aug 05, 2024	Jefferies	Buy	Buy	Hold
Jun 25, 2024	Cowen & Co.	Buy	Buy	Hold
May 07, 2024	JMP Securities	Outperform	Outperform	Hold
Sep 18, 2023	RBC Capital	-	Outperform	Upgrade
Aug 04, 2023	William Blair	-	Market Perform	Downgrade
Aug 04, 2023	Janney Montgomery	-	Buy	Upgrade

Row per page

Go to

BioCryst Pharmaceuticals's last stock rating was published by Piper Sandler on Nov 04, 2024. The company gave BCRX a "Overweight" rating, the same as its previous rate.

BioCryst Pharmaceuticals Financial Forecast

BioCryst Pharmaceuticals Revenue Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Mar 18	Mar 17
Revenue	-	-	-	-	-	-	-	-	-	$86.74M	$82.49M	$68.78M	$79.55M	$75.83M	$65.53M	$49.92M	$47.16M	$40.99M	$49.96M	$19.06M	$4.02M	$6.10M	$2.87M	$4.82M	$39.73M	$1.77M	$1.45M	$5.89M	$3.98M	$9.44M
Avg Forecast	$144.33M	$134.70M	$129.37M	$117.50M	$126.32M	$113.99M	$98.30M	$85.62M	$89.97M	$86.06M	$81.42M	$71.69M	$75.23M	$74.78M	$63.33M	$51.36M	$51.06M	$40.20M	$28.11M	$8.83M	$14.74M	$3.60M	$2.25M	$4.29M	$9.88M	$2.96M	$2.02M	$3.11M	$2.91M	$8.94M
High Forecast	$150.47M	$140.43M	$134.87M	$122.50M	$133.14M	$115.21M	$98.30M	$85.62M	$94.32M	$86.06M	$84.88M	$74.74M	$78.43M	$74.78M	$63.33M	$51.36M	$51.06M	$40.20M	$28.11M	$8.83M	$14.74M	$3.60M	$2.25M	$4.29M	$9.88M	$2.96M	$2.02M	$3.11M	$3.49M	$10.73M
Low Forecast	$134.58M	$125.60M	$120.63M	$109.57M	$109.64M	$112.78M	$98.30M	$85.62M	$86.55M	$86.06M	$75.92M	$66.85M	$70.15M	$74.78M	$63.33M	$51.36M	$51.06M	$40.20M	$28.11M	$8.83M	$14.74M	$3.60M	$2.25M	$4.29M	$9.88M	$2.96M	$2.02M	$3.11M	$2.32M	$7.15M
# Analysts	1	1	1	2	6	3	3	4	7	5	6	3	2	2	2	2	3	4	5	6	9	9	9	9	8	8	8	8	10	18
Surprise %	-	-	-	-	-	-	-	-	-	1.01%	1.01%	0.96%	1.06%	1.01%	1.03%	0.97%	0.92%	1.02%	1.78%	2.16%	0.27%	1.69%	1.27%	1.12%	4.02%	0.60%	0.72%	1.89%	1.37%	1.06%

BioCryst Pharmaceuticals's average Quarter revenue forecast for Dec 23 based on 7 analysts is $89.97M, with a low forecast of $86.55M, and a high forecast of $94.32M. BCRX's average Quarter revenue forecast represents a 3.72% increase compared to the company's last Quarter revenue of $86.74M (Sep 23).

BioCryst Pharmaceuticals EBITDA Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Mar 18	Mar 17
# Analysts	1	1	1	2	6	3	3	4	7	5	6	3	2	2	2	2	3	4	5	6	9	9	9	9	8	8	8	8	10	18
EBITDA	-	-	-	-	-	-	-	-	-	$-7.74M	$-16.95M	$-25.04M	$-43.61M	$-15.69M	$-34.11M	$-49.90M	$3.42M	$-44.46M	$-29.50M	$-51.20M	$-54.70M	$-42.71M	$-35.51M	$-34.33M	$650.00K	$-34.37M	$-34.41M	$-28.15M	$-23.37M	$-11.95M
Avg Forecast	$-110.76M	$-103.37M	$-99.28M	$-90.17M	$-96.94M	$-87.48M	$-75.44M	$-29.84M	$-69.04M	$-66.04M	$-62.48M	$-31.92M	$5.65M	$-57.39M	$-35.72M	$-39.41M	$-39.19M	$-30.85M	$-21.57M	$-34.13M	$-11.31M	$-2.77M	$-1.73M	$-34.33M	$-7.58M	$-2.27M	$-1.55M	$-27.11M	$-14.76M	$-11.28M
High Forecast	$-103.28M	$-96.39M	$-92.58M	$-84.08M	$-84.14M	$-86.55M	$-75.44M	$-23.87M	$-66.42M	$-66.04M	$-58.26M	$-25.53M	$6.78M	$-57.39M	$-28.57M	$-39.41M	$-39.19M	$-30.85M	$-21.57M	$-27.31M	$-11.31M	$-2.77M	$-1.73M	$-27.47M	$-7.58M	$-2.27M	$-1.55M	$-21.69M	$-11.81M	$-9.03M
Low Forecast	$-115.47M	$-107.77M	$-103.50M	$-94.01M	$-102.18M	$-88.41M	$-75.44M	$-35.81M	$-72.38M	$-66.04M	$-65.14M	$-38.30M	$4.52M	$-57.39M	$-42.86M	$-39.41M	$-39.19M	$-30.85M	$-21.57M	$-40.96M	$-11.31M	$-2.77M	$-1.73M	$-41.20M	$-7.58M	$-2.27M	$-1.55M	$-32.53M	$-17.71M	$-13.54M
Surprise %	-	-	-	-	-	-	-	-	-	0.12%	0.27%	0.78%	-7.72%	0.27%	0.96%	1.27%	-0.09%	1.44%	1.37%	1.50%	4.84%	15.44%	20.53%	1.00%	-0.09%	15.11%	22.21%	1.04%	1.58%	1.06%

2 analysts predict BCRX's average Quarter EBITDA for Mar 22 to be $-39.41M, with a high of $-39.41M and a low of $-39.41M. This is -1250.78% lower than BioCryst Pharmaceuticals's previous annual EBITDA (Dec 21) of $3.42M.

BioCryst Pharmaceuticals Net Income Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Mar 18	Mar 17
# Analysts	1	1	1	2	6	3	3	4	7	5	6	3	2	2	2	2	3	4	5	6	9	9	9	9	8	8	8	8	10	18
Net Income	-	-	-	-	-	-	-	-	-	$-36.15M	$-75.33M	$-53.33M	$-71.54M	$-42.52M	$-58.86M	$-74.20M	$-17.78M	$-58.80M	$-43.20M	$-64.28M	$-60.49M	$-46.12M	$-38.61M	$-37.60M	$-2.62M	$-37.59M	$-37.63M	$-31.05M	$-25.78M	$-14.22M
Avg Forecast	$-1.03M	$-8.28M	$-14.48M	$-21.73M	$-15.86M	$-14.25M	$-35.79M	$-37.47M	$-50.87M	$-50.69M	$-48.42M	$-40.07M	$-29.34M	$-58.92M	$-62.32M	$-74.83M	$-60.90M	$-60.43M	$-48.23M	$-42.86M	$-51.81M	$-52.64M	$-52.75M	$-37.60M	$-52.98M	$-66.06M	$-63.99M	$-29.90M	$-16.28M	$-13.43M
High Forecast	$-943.73K	$-7.55M	$-13.21M	$-19.82M	$-1.59M	$-13.00M	$-32.65M	$-29.97M	$-29.67M	$-46.24M	$-44.17M	$-32.06M	$-23.47M	$-58.92M	$-49.86M	$-74.83M	$-60.90M	$-60.43M	$-48.23M	$-34.28M	$-51.81M	$-52.64M	$-52.75M	$-30.08M	$-52.98M	$-66.06M	$-63.99M	$-23.92M	$-13.02M	$-10.74M
Low Forecast	$-1.09M	$-8.73M	$-15.28M	$-22.93M	$-30.14M	$-15.04M	$-37.77M	$-44.96M	$-80.55M	$-53.50M	$-51.09M	$-48.08M	$-35.20M	$-58.92M	$-74.79M	$-74.83M	$-60.90M	$-60.43M	$-48.23M	$-51.43M	$-51.81M	$-52.64M	$-52.75M	$-45.12M	$-52.98M	$-66.06M	$-63.99M	$-35.88M	$-19.54M	$-16.11M
Surprise %	-	-	-	-	-	-	-	-	-	0.71%	1.56%	1.33%	2.44%	0.72%	0.94%	0.99%	0.29%	0.97%	0.90%	1.50%	1.17%	0.88%	0.73%	1.00%	0.05%	0.57%	0.59%	1.04%	1.58%	1.06%

BioCryst Pharmaceuticals's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. BCRX's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).

BioCryst Pharmaceuticals SG&A Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Mar 18	Mar 17
# Analysts	1	1	1	2	6	3	3	4	7	5	6	3	2	2	2	2	3	4	5	6	9	9	9	9	8	8	8	8	10	18
SG&A	-	-	-	-	-	-	-	-	-	$50.65M	$51.00M	$47.87M	$50.15M	$36.92M	$38.02M	$34.28M	$35.39M	$34.99M	$26.32M	$22.11M	$20.99M	$17.20M	$13.88M	$15.87M	$10.49M	$11.73M	$8.66M	$6.24M	$7.61M	$3.06M
Avg Forecast	$189.46M	$176.82M	$169.82M	$154.25M	$165.82M	$149.64M	$129.05M	$12.89M	$118.11M	$112.97M	$106.88M	$13.78M	$58.39M	$98.17M	$40.25M	$67.42M	$67.03M	$52.77M	$36.90M	$11.59M	$19.35M	$4.73M	$2.96M	$5.63M	$12.96M	$3.89M	$2.65M	$4.08M	$3.81M	$2.89M
High Forecast	$197.52M	$184.34M	$177.05M	$160.81M	$174.78M	$151.24M	$129.05M	$15.47M	$123.81M	$112.97M	$111.43M	$16.54M	$70.07M	$98.17M	$48.30M	$67.42M	$67.03M	$52.77M	$36.90M	$11.59M	$19.35M	$4.73M	$2.96M	$5.63M	$12.96M	$3.89M	$2.65M	$4.08M	$4.58M	$3.47M
Low Forecast	$176.67M	$164.88M	$158.36M	$143.83M	$143.93M	$148.05M	$129.05M	$10.31M	$113.62M	$112.97M	$99.67M	$11.03M	$46.71M	$98.17M	$32.20M	$67.42M	$67.03M	$52.77M	$36.90M	$11.59M	$19.35M	$4.73M	$2.96M	$5.63M	$12.96M	$3.89M	$2.65M	$4.08M	$3.05M	$2.31M
Surprise %	-	-	-	-	-	-	-	-	-	0.45%	0.48%	3.47%	0.86%	0.38%	0.94%	0.51%	0.53%	0.66%	0.71%	1.91%	1.08%	3.63%	4.69%	2.82%	0.81%	3.02%	3.27%	1.53%	1.99%	1.06%

BioCryst Pharmaceuticals's average Quarter SG&A projection for Dec 23 is $118.11M, based on 7 Wall Street analysts, with a range of $113.62M to $123.81M. The forecast indicates a 133.19% rise compared to BCRX last annual SG&A of $50.65M (Sep 23).

BioCryst Pharmaceuticals EPS Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Mar 18	Mar 17
# Analysts	1	1	1	2	6	3	3	4	7	5	6	3	2	2	2	2	3	4	5	6	9	9	9	9	8	8	8	8	10	18
EPS	-	-	-	-	-	-	-	-	-	$-0.19	$-0.40	$-0.28	$-0.38	$-0.23	$-0.32	$-0.40	$-0.10	$-0.33	$-0.24	$-0.36	$-0.34	$-0.26	$-0.24	$-0.24	$-0.02	$-0.34	$-0.34	$-0.28	$-0.26	$-0.19
Avg Forecast	$-0.01	$-0.04	$-0.07	$-0.10	$-0.08	$-0.07	$-0.17	$-0.21	$-0.25	$-0.24	$-0.23	$-0.30	$-0.17	$-0.29	$-0.34	$-0.36	$-0.29	$-0.29	$-0.23	$-0.27	$-0.25	$-0.26	$-0.26	$-0.24	$-0.26	$-0.32	$-0.31	$-0.27	$-0.12	$-0.17
High Forecast	$-0.00	$-0.04	$-0.06	$-0.10	$-0.01	$-0.06	$-0.16	$-0.19	$-0.14	$-0.22	$-0.21	$-0.27	$-0.15	$-0.29	$-0.34	$-0.36	$-0.29	$-0.29	$-0.23	$-0.27	$-0.25	$-0.26	$-0.26	$-0.24	$-0.26	$-0.32	$-0.31	$-0.27	$-0.10	$-0.14
Low Forecast	$-0.01	$-0.04	$-0.07	$-0.11	$-0.15	$-0.07	$-0.18	$-0.22	$-0.39	$-0.26	$-0.25	$-0.32	$-0.18	$-0.29	$-0.34	$-0.36	$-0.29	$-0.29	$-0.23	$-0.27	$-0.25	$-0.26	$-0.26	$-0.24	$-0.26	$-0.32	$-0.31	$-0.27	$-0.14	$-0.20
Surprise %	-	-	-	-	-	-	-	-	-	0.78%	1.71%	0.94%	2.28%	0.81%	0.93%	1.10%	0.33%	1.13%	1.03%	1.35%	1.35%	1.02%	0.94%	0.99%	0.08%	1.06%	1.10%	1.03%	2.17%	1.12%

According to undefined Wall Street analysts, BioCryst Pharmaceuticals's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to BCRX previous annual EPS of $NaN (undefined).

BioCryst Pharmaceuticals Peer Comparison by Price Target

Ticker	Company	Last Closing Price	Avg Price Target	Upside/Downside	Avg Rating
XFOR	X4 Pharmaceuticals	$0.28	$3.67	1210.71%	Buy
IMUX	Immunic	$1.17	$5.00	327.35%	Buy
INMB	INmune Bio	$5.72	$22.00	284.62%	Buy
PDSB	PDS Bio	$2.76	$9.00	226.09%	Buy
APLS	Apellis Pharmaceuticals	$28.25	$74.50	163.72%	Buy
DAWN	Day One Biopharmaceuticals	$14.85	$38.80	161.28%	Buy
KZR	Kezar Life Sciences	$7.54	$17.50	132.10%	Buy
MCRB	Seres Therapeutics	$0.59	$1.25	111.86%	Buy
BCRX	BioCryst Pharmaceuticals	$7.64	$16.00	109.42%	Buy
VKTX	Viking Therapeutics	$55.06	$102.40	85.98%	Buy
AXSM	Axsome Therapeutics	$97.83	$122.42	25.14%	Buy
AVXL	Anavex Life Sciences	$8.89	$11.00	23.73%	Buy
BPMC	Blueprint Medicines	$96.88	$109.71	13.24%	Buy
MDGL	Madrigal Pharmaceuticals	$315.15	$315.75	0.19%	Buy
TGTX	TG Therapeutics	$34.90	$27.60	-20.92%	Buy
KRTX	Karuna Therapeutics	$329.83	$257.50	-21.93%	Buy
ATRA	Atara Biotherapeutics	$14.26	$10.33	-27.56%	Sell

BCRX Forecast FAQ

Is BioCryst Pharmaceuticals a good buy?

Yes, according to 15 Wall Street analysts, BioCryst Pharmaceuticals (BCRX) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 12 'Buy' recommendations, accounting for 80.00% of BCRX's total ratings.

What is BCRX's price target?

BioCryst Pharmaceuticals (BCRX) average price target is $16 with a range of $7 to $25, implying a 109.42% from its last price of $7.64. The data is based on 15 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will BioCryst Pharmaceuticals stock go up soon?

According to Wall Street analysts' prediction for BCRX stock, the company can go up by 109.42% (from the last price of $7.64 to the average price target of $16), up by 227.23% based on the highest stock price target, and down by -8.38% based on the lowest stock price target.

Can BioCryst Pharmaceuticals stock reach $11?

BCRX's average twelve months analyst stock price target of $16 supports the claim that BioCryst Pharmaceuticals can reach $11 in the near future.

What are BioCryst Pharmaceuticals's analysts' financial forecasts?

BioCryst Pharmaceuticals's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $424.23M (high $432.27M, low $406.34M), average EBITDA is $-290M (high $-270M, low $-302M), average net income is $-103M (high $-77.215M, low $-128M), average SG&A $457.4M (high $470.53M, low $431.34M), and average EPS is $-0.528 (high $-0.419, low $-0.622). BCRX's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $525.89M (high $548.27M, low $490.39M), average EBITDA is $-404M (high $-376M, low $-421M), average net income is $-45.519M (high $-41.524M, low $-48.038M), average SG&A $690.35M (high $719.73M, low $643.74M), and average EPS is $-0.22 (high $-0.201, low $-0.232).

Did the BCRX's actual financial results beat the analysts' financial forecasts?

Based on BioCryst Pharmaceuticals's last annual report (Dec 2023), the company's revenue was $331.41M, beating the average analysts forecast of $329.13M by 0.69%. Apple's EBITDA was $-104M, missing the average prediction of $-229M by -54.81%. The company's net income was $-227M, beating the average estimation of $-190M by 19.20%. Apple's SG&A was $213.89M, missing the average forecast of $351.75M by -39.19%. Lastly, the company's EPS was $-1.18, beating the average prediction of $-1.024 by 15.28%. In terms of the last quarterly report (Sep 2023), BioCryst Pharmaceuticals's revenue was $86.74M, beating the average analysts' forecast of $86.06M by 0.79%. The company's EBITDA was $-7.737M, missing the average prediction of $-66.044M by -88.29%. BioCryst Pharmaceuticals's net income was $-36.149M, missing the average estimation of $-50.692M by -28.69%. The company's SG&A was $50.65M, missing the average forecast of $112.97M by -55.17%. Lastly, the company's EPS was $-0.19, missing the average prediction of $-0.245 by -22.45%